Animal Drug Compounding Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Anti-infective Agents, Anti-inflammatory Agents, Hormones & Substitutes, CNS Agents, Others), By Animal Type (Companion Animal, Livestock Animal), By Route of Administration (Oral, Injectable, Topical, Others), By Region and Competition, 2020-2030F

Market Overview

Global Animal Drug Compounding Market was valued at USD 1.63 Billion in 2024 and is expected to reach USD 2.61 Billion in the forecast period with a CAGR of 8.14% through 2030. The Global Animal Drug Compounding Market is experiencing significant growth as pet ownership continues to rise and the need for personalized veterinary care increases. Compounding pharmacies offer customized medication tailored to the unique needs of animals, especially when commercial drugs are not available or effective. This market is being driven by the growing recognition among pet owners and veterinarians of the benefits of compounded drugs. Pets, like humans, have specific health conditions that may require individualized treatment, prompting a surge in demand for customized solutions. These medications are particularly important for managing chronic conditions, allergies, or rare diseases, where standardized treatments often fall short. The increasing willingness of pet owners to invest in their pets’ healthcare is further boosting this demand, expanding the market for animal drug compounding services.

Key trends in the market include the ongoing advancements in veterinary compounding technologies, which enable the creation of more effective and precise formulations. Technological innovations, such as improved drug delivery systems and the use of novel excipients, are enhancing the quality of compounded medications. Veterinary professionals are increasingly relying on these advanced formulations to provide better treatment options for a range of animal diseases. Moreover, as veterinary practices shift towards more individualized care, there is a noticeable rise in the demand for compounded drugs for both companion animals and livestock. This trend is coupled with an increased focus on regulatory compliance, ensuring that compounded medications meet the required safety and efficacy standards. These technological developments are anticipated to further fuel the market growth in the coming years.

Despite the promising growth, the market faces several challenges that could impact its trajectory. One of the primary concerns is the lack of uniformity in regulations and guidelines surrounding animal drug compounding. While veterinary compounding pharmacies are subject to regulatory standards, the absence of universal global guidelines makes it difficult to ensure consistent quality and safety across regions. This variation in regulations can lead to market fragmentation, complicating the supply chain and limiting access to compounded drugs in some areas. Furthermore, there are concerns regarding the long-term safety and efficacy of compounded drugs due to limited clinical data, which may create hesitation among some veterinary professionals. Addressing these regulatory inconsistencies and building stronger clinical evidence for compounded medications will be crucial for sustaining market growth and maintaining consumer trust in the industry.

Key Market Drivers

Growing Pet Ownership and Awareness of Animal Health

The Global Animal Drug Compounding Market is experiencing significant growth, driven by the increasing pet ownership and heightened awareness of animal health. As of 2024, approximately 66% of U.S. households, equating to 86.9 million homes, own a pet, marking a substantial rise from 56% in 1988. This upward trend in pet ownership is mirrored globally, with millions of households embracing pets as integral family members.

Concurrently, there is a growing recognition among pet owners of the importance of comprehensive healthcare for their animals. This awareness has led to increased spending on pet health, including veterinary services, medications, and preventive care. In the United States alone, pet owners spent USD 89 billion on their pets in 2023, reflecting a 16% increase in pet food sales compared to previous years. This surge in expenditure underscores the prioritization of pet health and wellness.

The combination of rising pet ownership and enhanced health consciousness among owners has spurred demand for personalized veterinary care. Compounded medications offer tailored solutions for various animal health conditions, addressing specific needs that standard pharmaceuticals may not meet. This is particularly evident in the growing market for pet health products and services.

Advancements in Compounding Technology

Advancements in compounding technology are significantly driving the Global Animal Drug Compounding Market. The evolution of compounding practices has enabled the creation of customized medications tailored to the specific needs of individual animals, addressing conditions where standard pharmaceuticals may not be effective. This customization is particularly beneficial for managing chronic diseases, allergies, and other health issues prevalent in pets.

The U.S. Food and Drug Administration (FDA) has recognized the importance of compounding in veterinary medicine and has established guidelines to ensure the safety and efficacy of compounded animal drugs. In April 2022, the FDA issued final Guidance for Industry (GFI) #256, titled "Compounding Animal Drugs from Bulk Drug Substances," to help protect animal health by balancing the need for access to compounded drugs with the necessity of ensuring their safety and effectiveness.

The FDA's Veterinary Innovation Program (VIP), launched in October 2018, further supports the development of innovative veterinary products, including compounded medications. The program aims to provide greater certainty in the regulatory process, encourage development and research, and support an efficient and predictable regulatory approach for emerging veterinary products. These regulatory advancements have facilitated the integration of new technologies into veterinary compounding practices. Emerging technologies, such as animal cells, tissues, and cell- and tissue-based products (ACTPs), offer potential novel therapies for various veterinary medical needs, including musculoskeletal diseases and inflammatory conditions. The FDA is committed to using a science- and risk-based approach to regulate products of emerging technologies, ensuring consumer confidence and fostering the development of products that improve animal health.

Increasing Incidence of Chronic Diseases in Animals

The increasing incidence of chronic diseases in animals significantly drives the Global Animal Drug Compounding Market. As pets live longer due to advancements in veterinary care and improved nutrition, they become more susceptible to chronic conditions such as arthritis, diabetes, and kidney disease. For instance, chronic kidney disease (CKD) is prevalent among cats, with studies indicating that approximately 30% of cats over the age of 15 are affected.

This rise in chronic conditions has led to an increased demand for personalized and effective treatment options. Compounded medications offer tailored solutions that address specific health needs, providing veterinarians with the flexibility to adjust dosages and formulations to suit individual animals. Such customization is particularly beneficial for managing chronic diseases, where standard medications may not be effective or suitable.

The growing prevalence of chronic diseases in animals underscores the need for specialized treatments, thereby driving the demand for compounded medications. As pet owners become more aware of these health issues and seek effective management strategies, the market for animal drug compounding continues to expand, offering opportunities for innovation and growth in veterinary pharmaceutical services.

Download Free Sample Report

Key Market Challenges

Limited Awareness and Education

Limited awareness and education represent significant challenges for the Global Animal Drug Compounding Market. The lack of comprehensive knowledge regarding compounded medications among veterinarians and pet owners is a primary concern. Many veterinary professionals may not be fully aware of the potential benefits of compounded medications in managing complex animal health issues. This gap in awareness limits the widespread adoption of compounded drugs, particularly in regions where traditional pharmaceutical solutions are more commonly used. In addition to the professional knowledge gap, pet owners often lack understanding of the availability and effectiveness of compounded medications. This is compounded by the limited visibility of compounded drugs in mainstream veterinary practices and pharmacies. Without clear communication and education about how compounded medications can offer tailored solutions to treat specific health conditions in animals, pet owners may be hesitant to consider them as a viable option.

Veterinary schools and training programs are increasingly integrating pharmaceutical compounding into their curriculums. However, there is still a need for greater focus on educating the next generation of veterinarians about the benefits of compounding. Without proper education, many veterinarians may not feel confident in recommending compounded solutions, leaving compounded medications underutilized in veterinary care.

The lack of awareness extends to regulatory bodies, which have not consistently promoted the benefits and safety of compounded medications. Efforts from organizations such as the U.S. Food and Drug Administration (FDA) and other regulatory bodies to educate both veterinarians and pet owners on compounding guidelines and standards are still in the early stages, which hinders wider adoption.

Lack of Clinical Data and Research

Lack of clinical data and research poses a significant challenge for the Global Animal Drug Compounding Market. Despite the growing demand for personalized veterinary care, compounded medications often face scrutiny due to the limited availability of robust clinical studies supporting their safety and efficacy. Many compounded medications are formulated based on veterinary professionals' expertise rather than extensive clinical trials, leading to uncertainties about their long-term effects and optimal usage.

Compounding pharmacies typically rely on established pharmacological knowledge and guidelines, but the absence of peer-reviewed studies leaves a gap in evidence that veterinarians and pet owners can use to assess the risks and benefits of these treatments. The lack of large-scale, well-controlled studies in the veterinary compounding sector means that many veterinarians are hesitant to embrace compounded medications, especially when alternative treatments with more established clinical backing are available.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) have set guidelines for compounding animal medications, but these guidelines often lack the comprehensive clinical data that would reassure practitioners about the safety and efficacy of compounded treatments. The limited research also makes it challenging to address concerns related to the consistency and quality of compounded medications across different compounding pharmacies. The scarcity of clinical trials in veterinary compounding hampers the ability to standardize dosing, formulation, and treatment protocols, contributing to a lack of confidence in compounded drugs among veterinarians. Without more clinical data, veterinarians may opt for conventional treatments with a more established evidence base, further hindering the growth of the animal drug compounding market. Enhanced research and clinical trials are needed to build credibility and foster wider adoption of compounded medications in veterinary care.

Key Market Trends

Increased Demand for Personalized Veterinary Medicine

The increased demand for personalized veterinary medicine is a prominent trend driving the Global Animal Drug Compounding Market. As pet owners increasingly view their animals as family members, there is a growing desire for customized healthcare solutions that cater to the specific needs of individual animals. This shift towards personalized care has led to an upsurge in the use of compounded medications, which offer tailored treatments for various conditions, including chronic diseases, allergies, and age-related ailments.

Compounded drugs allow veterinarians to modify the strength, dosage, and form of medications to suit the unique needs of different animals, including companion pets, exotic animals, and livestock. Such flexibility is essential in treating conditions that may not respond well to commercially available medications. The ability to create customized formulations, such as flavored oral suspensions for finicky pets or specific dosages for small animals, increases treatment adherence and enhances the overall effectiveness of care.

As the awareness of animal health issues grows, veterinarians are recognizing the benefits of personalized medicine. Pet owners increasingly seek medications that cater to their pet’s unique health conditions, leading to a higher demand for compounded solutions. The ability to address specific needs, such as hypoallergenic formulas or medications tailored for animals with multiple health conditions, is a driving force behind the demand for personalized veterinary care.

This trend aligns with the broader healthcare sector's movement toward precision medicine, where treatments are tailored to an individual’s unique genetic makeup, environment, and lifestyle. In veterinary medicine, this approach provides significant improvements in the quality of care and outcomes. As pet owners become more knowledgeable and engaged in their pets’ health, the demand for personalized veterinary medicine, supported by compounded drugs, is expected to continue growing, driving the market forward.

Growth of Veterinary Compounding Pharmacies

The growth of veterinary compounding pharmacies is a key trend influencing the Global Animal Drug Compounding Market. These pharmacies specialize in preparing customized medications that are tailored to the specific needs of animals, offering solutions that cannot be met by commercially available pharmaceutical products. As pet ownership continues to rise globally, there is an increasing demand for specialized and personalized care, propelling the expansion of veterinary compounding pharmacies.

The ability of these pharmacies to create individualized treatments is particularly important for managing conditions that require specialized formulations, such as chronic illnesses, behavioral disorders, or drug allergies in pets. Many animals, especially those with unique health needs, may not respond to mass-produced drugs, which makes compounded medications a crucial alternative. Veterinary compounding pharmacies are equipped to provide customized medications in various forms, including oral suspensions, transdermal gels, and injectable solutions, to meet the diverse needs of animals.

The regulatory landscape for veterinary compounding has also evolved, allowing compounding pharmacies to operate under clearer guidelines. These regulatory advancements ensure the safety and quality of compounded medications, which, in turn, boosts consumer and veterinary confidence. As a result, the growth of veterinary compounding pharmacies is expected to continue, driven by the rising demand for personalized treatments and the need for specialized care in veterinary medicine.

Segmental Insights

Product Insights

Based on the Product, CNS Agents emerged as the dominant segment in the Global Animal Drug Compounding Market in 2024. This is driven by the increasing prevalence of neurological disorders in companion animals. Pets, particularly dogs and cats, are susceptible to a variety of neurological conditions such as epilepsy, anxiety, and degenerative diseases, which require specialized treatment. Compounded CNS medications allow veterinarians to create tailored solutions that address the specific needs of animals, including adjusting dosages and formulations to improve efficacy and minimize side effects.

The rising awareness among pet owners about the importance of managing behavioral and neurological disorders in pets has significantly contributed to the demand for CNS agents. Furthermore, many off-the-shelf medications are not suitable or effective for certain animal species or conditions, driving the need for customized compounded formulations. These medications are often more palatable, available in easier-to-administer forms, and can be tailored to suit an individual animal’s specific health needs. Veterinary practices are increasingly recognizing the benefits of compounded CNS medications, which has further strengthened the growth of this segment. As the veterinary care industry continues to advance and the focus on holistic, personalized treatments increases, CNS agents are expected to remain a dominant product category in the animal drug compounding market.

Route of Administration Insights

Based on the Route of Administration, Oral emerged as the dominant segment in the Global Animal Drug Compounding Market in 2024. This dominance is primarily due to its ease of use and effectiveness in delivering medications to a wide range of animal species. Oral medications are often the most convenient and cost-effective option for both veterinarians and pet owners, especially when it comes to long-term treatment for chronic conditions. This route of administration allows for precise dosage control and is suitable for a variety of compounded formulations, such as flavored tablets, liquids, or capsules, making it easier to administer to animals, particularly pets, who may be difficult to treat with injections or topical medications.

The high demand for oral medications can also be attributed to the growing focus on improving animal compliance with treatments. Many animals, especially companion animals, are more likely to accept oral medications when they are formulated in palatable flavors, reducing the stress for both the pet and the owner. Oral administration is also advantageous for managing common conditions such as infections, gastrointestinal issues, and behavioral disorders, which are frequently treated with compounded drugs. As the veterinary market continues to prioritize convenience and compliance, oral administration is expected to maintain its dominance in the animal drug compounding market.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Animal Drug Compounding Market in 2024. This is primarily driven by several key factors. The region has a highly developed veterinary healthcare system, with a large number of veterinary clinics and compounding pharmacies offering specialized services. The growing awareness among pet owners about the benefits of personalized treatments for animals is fueling demand for compounded medications, particularly for companion animals. The increase in pet ownership and the rising focus on pet health and wellness have led to higher expenditure on veterinary care, further boosting the market for compounded drugs.

Additionally, North America has witnessed significant advancements in compounding technologies, enabling the production of more precise and effective medications tailored to the needs of different animal species. The regulatory environment in the region is also well-established, with clear guidelines for the preparation and distribution of compounded medications, ensuring the safety and efficacy of these drugs. The increasing prevalence of chronic diseases in pets, such as arthritis, diabetes, and anxiety, has driven the demand for long-term, customized treatments that are often provided through compounded medications. As a result, North America remains a key market for animal drug compounding, with continued growth expected in the coming years.

Recent Developments

• In November 2024, My Compounding, a prominent compounding pharmacy based in Brisbane, revealed its plans for nationwide expansion, providing personalized medication solutions throughout the country. This move positions the pharmacy as a key contributor to advancing customized healthcare services for patients across the nation.
• In November 2024, Fidelis Animal Health, Inc. received FDA approval for Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL to control post-procedural pain in captive rodents and laboratory rabbits. Ethiqa XR provides veterinarians with an FDA-indexed, cGMP pharmaceutical-grade extended-release buprenorphine for use in various species, including mice, rats, gerbils, hamsters, chinchillas, guinea pigs, prairie dogs, ferrets, laboratory rabbits, and non-human primates.
• In September 2024, Wedgewood announced the addition of molnupiravir to its formulary for the treatment of Feline Infectious Peritonitis (FIP). Originally developed for human viral infections, molnupiravir has shown promise as a first- and second-line therapy for FIP, a disease affecting approximately 15,000 cats in the US annually. Wedgewood will be the first US veterinary compounding pharmacy to offer feline-friendly formulations, including flavored oral oil suspensions and various capsule doses, tailored to different FIP forms.
• In May 2024, Mixlab acquired NexGen Animal Health, extending its advanced compounding pharmacy services from companion animals to include large animals. The company intends to leverage its proprietary technology platform to enhance the pharmacy experience for large animal veterinarians and owners, while improving production efficiency and supporting ongoing growth.

Key Market Players

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

Report Scope:

In this report, the Global Animal Drug Compounding Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Animal Drug Compounding Market, By Product:

o   Anti-infective Agents

o   Anti-inflammatory Agents

o   Hormones & Substitutes

o   CNS Agents

o   Others

• Animal Drug Compounding Market, By Animal Type:

o   Companion Animal

o   Livestock Animal

• Animal Drug Compounding Market, By Route of Administration:

o   Oral

o   Injectable

o   Topical

o   Others

• Animal Drug Compounding Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Drug Compounding Market.

Available Customizations:

Global Animal Drug Compounding Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Animal Drug Compounding Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]